Glutamate cycle changes in the putamen of patients with de novo Parkinson's disease using 1H MRS
To investigate glutamatergic metabolism changes in the putamen of patients with de novo Parkinson's Disease (PD) and test the hypothesis that glutamate (Glu) levels are abnormally elevated in the putamen contralateral to where the motor clinical signs predominate as expected from observations i...
Gespeichert in:
| Veröffentlicht in: | Parkinsonism & related disorders 2022-06, Vol.99, p.65-72 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 72 |
|---|---|
| container_issue | |
| container_start_page | 65 |
| container_title | Parkinsonism & related disorders |
| container_volume | 99 |
| creator | Chassain, Carine Cladiere, Aurélie Tsoutsos, Camille Pereira, Bruno Boumezbeur, Fawzi Debilly, Bérangère Marques, Ana-Raquel Thobois, Stéphane Durif, Franck |
| description | To investigate glutamatergic metabolism changes in the putamen of patients with de novo Parkinson's Disease (PD) and test the hypothesis that glutamate (Glu) levels are abnormally elevated in the putamen contralateral to where the motor clinical signs predominate as expected from observations in animal models.
1H NMR spectra from 17 healthy control volunteers were compared with spectra from 17 de novo PD patients of who 14 were evaluated again after 2–3 years of disease progression. Statistical analysis used random-effects models.
The only significant difference between PD patients and controls was a higher glutamine (Gln) concentration in the putamen ipsilateral to the hemibody with predominant motor signs (Visit 1: 6.0 ± 0.4 mM vs. 5.2 ± 0.2 mM, p |
| doi_str_mv | 10.1016/j.parkreldis.2022.05.007 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03882060v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1353802022001341</els_id><sourcerecordid>2670063366</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2807-a072717e5932ce4584efec85b05867d9ea959375c433437c5f8478267d9778f23</originalsourceid><addsrcrecordid>eNqFkUFv3CAQhVHUKknT_gduSQ92BzCGPaZRm620VaMkPVOCx1k2XnDBu1H-fbC2ao-9AJr3zdMwjxDKoGbA2k-berTpKeHQ-Vxz4LwGWQOoI3LKtBKVZLx9U95CikoDhxPyLucNFEKCOCYnQrazJk_Jr-thN9mtnZC6FzeUc23DI2bqA53WSMdZxUBjT0c7eQxTps9-WtMOaYj7SG_KID7kGM4zLdOgzUh32YdHypb0--3de_K2t0PGD3_uM_Lz65f7q2W1-nH97epyVTmuQVUWFFdMoVwI7rCRusEenZYPIHWrugXaRZGUdI0QjVBO9rpRms-SUrrn4ox8PPiu7WDG5Lc2vZhovVlersxcA6E1hxb2rLAXB3ZM8fcO82S2PjscBhsw7rIptgCtEG1bUH1AXYo5J-z_ejMwcxZmY_5lYeYsDEhTNl1aPx9asXx77zGZ7MoCHXY-oZtMF_3_TV4BlJaThQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2670063366</pqid></control><display><type>article</type><title>Glutamate cycle changes in the putamen of patients with de novo Parkinson's disease using 1H MRS</title><source>Access via ScienceDirect (Elsevier)</source><creator>Chassain, Carine ; Cladiere, Aurélie ; Tsoutsos, Camille ; Pereira, Bruno ; Boumezbeur, Fawzi ; Debilly, Bérangère ; Marques, Ana-Raquel ; Thobois, Stéphane ; Durif, Franck</creator><creatorcontrib>Chassain, Carine ; Cladiere, Aurélie ; Tsoutsos, Camille ; Pereira, Bruno ; Boumezbeur, Fawzi ; Debilly, Bérangère ; Marques, Ana-Raquel ; Thobois, Stéphane ; Durif, Franck</creatorcontrib><description><![CDATA[To investigate glutamatergic metabolism changes in the putamen of patients with de novo Parkinson's Disease (PD) and test the hypothesis that glutamate (Glu) levels are abnormally elevated in the putamen contralateral to where the motor clinical signs predominate as expected from observations in animal models.
1H NMR spectra from 17 healthy control volunteers were compared with spectra from 17 de novo PD patients of who 14 were evaluated again after 2–3 years of disease progression. Statistical analysis used random-effects models.
The only significant difference between PD patients and controls was a higher glutamine (Gln) concentration in the putamen ipsilateral to the hemibody with predominant motor signs (Visit 1: 6.0 ± 0.4 mM vs. 5.2 ± 0.2 mM, p < 0.05; Visit 2: 6.2 ± 0.3 mM vs. 5.2 ± 0.2 mM, p < 0.05). At Visit 1, PD patients had higher Glu and Gln levels in the putamen ipsilateral versus contralateral to dominant clinical signs (Glu: 12.2 ± 0.6 mM vs. 10.4 ± 0.6 mM, p < 0.05; Gln: 6.0 ± 0.4 mM vs. 4.8 ± 0.4 mM, p < 0.05; Glu and Gln pool (Glx): 17.9 ± 0.8 mM vs. 14.7 ± 1.1 mM, p < 0.05). At Visit 2, the sum of the two metabolites remained significantly higher in the ipsilateral versus contralateral putamen (Glx: 18.3 ± 0.6 mM vs. 16.1 ± 0.9 mM, p < 0.05).
In de novo PD patients, the putamen ipsilateral to the more affected hemibody showed elevated Gln versus controls and elevated Glu and Gln concentrations versus the contralateral side. Abnormalities in Glu metabolism therefore occur early in PD but unexpectedly in the putamen contralateral to the more damaged hemisphere, suggesting they are not dependent solely on dopamine loss.
•MRS assesses glutamate, glutamine levels from the putamen of de novo parkinsonian patients.•Glutamate, glutamine levels are higher in the putamen ipsilateral to clinical signs.•Abnormalities in Glutamate metabolism therefore occur early in Parkinson Disease.•However, changes occur unexpectedly in the putamen of the less damaged hemisphere.•Metabolic changes are not dependent solely on dopamine loss.]]></description><identifier>ISSN: 1353-8020</identifier><identifier>EISSN: 1873-5126</identifier><identifier>DOI: 10.1016/j.parkreldis.2022.05.007</identifier><identifier>PMID: 35613535</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>1H magnetic Resonance spectroscopy ; Glutamate ; Glutamine ; Life Sciences ; Neurons and Cognition ; Parkinson's disease ; Putamen</subject><ispartof>Parkinsonism & related disorders, 2022-06, Vol.99, p.65-72</ispartof><rights>2022 The Authors</rights><rights>Attribution - NonCommercial - NoDerivatives</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2807-a072717e5932ce4584efec85b05867d9ea959375c433437c5f8478267d9778f23</citedby><cites>FETCH-LOGICAL-c2807-a072717e5932ce4584efec85b05867d9ea959375c433437c5f8478267d9778f23</cites><orcidid>0000-0003-3778-7161 ; 0000-0002-9234-2344 ; 0000-0002-3786-1053</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.parkreldis.2022.05.007$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://hal.inrae.fr/hal-03882060$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Chassain, Carine</creatorcontrib><creatorcontrib>Cladiere, Aurélie</creatorcontrib><creatorcontrib>Tsoutsos, Camille</creatorcontrib><creatorcontrib>Pereira, Bruno</creatorcontrib><creatorcontrib>Boumezbeur, Fawzi</creatorcontrib><creatorcontrib>Debilly, Bérangère</creatorcontrib><creatorcontrib>Marques, Ana-Raquel</creatorcontrib><creatorcontrib>Thobois, Stéphane</creatorcontrib><creatorcontrib>Durif, Franck</creatorcontrib><title>Glutamate cycle changes in the putamen of patients with de novo Parkinson's disease using 1H MRS</title><title>Parkinsonism & related disorders</title><description><![CDATA[To investigate glutamatergic metabolism changes in the putamen of patients with de novo Parkinson's Disease (PD) and test the hypothesis that glutamate (Glu) levels are abnormally elevated in the putamen contralateral to where the motor clinical signs predominate as expected from observations in animal models.
1H NMR spectra from 17 healthy control volunteers were compared with spectra from 17 de novo PD patients of who 14 were evaluated again after 2–3 years of disease progression. Statistical analysis used random-effects models.
The only significant difference between PD patients and controls was a higher glutamine (Gln) concentration in the putamen ipsilateral to the hemibody with predominant motor signs (Visit 1: 6.0 ± 0.4 mM vs. 5.2 ± 0.2 mM, p < 0.05; Visit 2: 6.2 ± 0.3 mM vs. 5.2 ± 0.2 mM, p < 0.05). At Visit 1, PD patients had higher Glu and Gln levels in the putamen ipsilateral versus contralateral to dominant clinical signs (Glu: 12.2 ± 0.6 mM vs. 10.4 ± 0.6 mM, p < 0.05; Gln: 6.0 ± 0.4 mM vs. 4.8 ± 0.4 mM, p < 0.05; Glu and Gln pool (Glx): 17.9 ± 0.8 mM vs. 14.7 ± 1.1 mM, p < 0.05). At Visit 2, the sum of the two metabolites remained significantly higher in the ipsilateral versus contralateral putamen (Glx: 18.3 ± 0.6 mM vs. 16.1 ± 0.9 mM, p < 0.05).
In de novo PD patients, the putamen ipsilateral to the more affected hemibody showed elevated Gln versus controls and elevated Glu and Gln concentrations versus the contralateral side. Abnormalities in Glu metabolism therefore occur early in PD but unexpectedly in the putamen contralateral to the more damaged hemisphere, suggesting they are not dependent solely on dopamine loss.
•MRS assesses glutamate, glutamine levels from the putamen of de novo parkinsonian patients.•Glutamate, glutamine levels are higher in the putamen ipsilateral to clinical signs.•Abnormalities in Glutamate metabolism therefore occur early in Parkinson Disease.•However, changes occur unexpectedly in the putamen of the less damaged hemisphere.•Metabolic changes are not dependent solely on dopamine loss.]]></description><subject>1H magnetic Resonance spectroscopy</subject><subject>Glutamate</subject><subject>Glutamine</subject><subject>Life Sciences</subject><subject>Neurons and Cognition</subject><subject>Parkinson's disease</subject><subject>Putamen</subject><issn>1353-8020</issn><issn>1873-5126</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkUFv3CAQhVHUKknT_gduSQ92BzCGPaZRm620VaMkPVOCx1k2XnDBu1H-fbC2ao-9AJr3zdMwjxDKoGbA2k-berTpKeHQ-Vxz4LwGWQOoI3LKtBKVZLx9U95CikoDhxPyLucNFEKCOCYnQrazJk_Jr-thN9mtnZC6FzeUc23DI2bqA53WSMdZxUBjT0c7eQxTps9-WtMOaYj7SG_KID7kGM4zLdOgzUh32YdHypb0--3de_K2t0PGD3_uM_Lz65f7q2W1-nH97epyVTmuQVUWFFdMoVwI7rCRusEenZYPIHWrugXaRZGUdI0QjVBO9rpRms-SUrrn4ox8PPiu7WDG5Lc2vZhovVlersxcA6E1hxb2rLAXB3ZM8fcO82S2PjscBhsw7rIptgCtEG1bUH1AXYo5J-z_ejMwcxZmY_5lYeYsDEhTNl1aPx9asXx77zGZ7MoCHXY-oZtMF_3_TV4BlJaThQ</recordid><startdate>202206</startdate><enddate>202206</enddate><creator>Chassain, Carine</creator><creator>Cladiere, Aurélie</creator><creator>Tsoutsos, Camille</creator><creator>Pereira, Bruno</creator><creator>Boumezbeur, Fawzi</creator><creator>Debilly, Bérangère</creator><creator>Marques, Ana-Raquel</creator><creator>Thobois, Stéphane</creator><creator>Durif, Franck</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0003-3778-7161</orcidid><orcidid>https://orcid.org/0000-0002-9234-2344</orcidid><orcidid>https://orcid.org/0000-0002-3786-1053</orcidid></search><sort><creationdate>202206</creationdate><title>Glutamate cycle changes in the putamen of patients with de novo Parkinson's disease using 1H MRS</title><author>Chassain, Carine ; Cladiere, Aurélie ; Tsoutsos, Camille ; Pereira, Bruno ; Boumezbeur, Fawzi ; Debilly, Bérangère ; Marques, Ana-Raquel ; Thobois, Stéphane ; Durif, Franck</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2807-a072717e5932ce4584efec85b05867d9ea959375c433437c5f8478267d9778f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>1H magnetic Resonance spectroscopy</topic><topic>Glutamate</topic><topic>Glutamine</topic><topic>Life Sciences</topic><topic>Neurons and Cognition</topic><topic>Parkinson's disease</topic><topic>Putamen</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chassain, Carine</creatorcontrib><creatorcontrib>Cladiere, Aurélie</creatorcontrib><creatorcontrib>Tsoutsos, Camille</creatorcontrib><creatorcontrib>Pereira, Bruno</creatorcontrib><creatorcontrib>Boumezbeur, Fawzi</creatorcontrib><creatorcontrib>Debilly, Bérangère</creatorcontrib><creatorcontrib>Marques, Ana-Raquel</creatorcontrib><creatorcontrib>Thobois, Stéphane</creatorcontrib><creatorcontrib>Durif, Franck</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Parkinsonism & related disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chassain, Carine</au><au>Cladiere, Aurélie</au><au>Tsoutsos, Camille</au><au>Pereira, Bruno</au><au>Boumezbeur, Fawzi</au><au>Debilly, Bérangère</au><au>Marques, Ana-Raquel</au><au>Thobois, Stéphane</au><au>Durif, Franck</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glutamate cycle changes in the putamen of patients with de novo Parkinson's disease using 1H MRS</atitle><jtitle>Parkinsonism & related disorders</jtitle><date>2022-06</date><risdate>2022</risdate><volume>99</volume><spage>65</spage><epage>72</epage><pages>65-72</pages><issn>1353-8020</issn><eissn>1873-5126</eissn><abstract><![CDATA[To investigate glutamatergic metabolism changes in the putamen of patients with de novo Parkinson's Disease (PD) and test the hypothesis that glutamate (Glu) levels are abnormally elevated in the putamen contralateral to where the motor clinical signs predominate as expected from observations in animal models.
1H NMR spectra from 17 healthy control volunteers were compared with spectra from 17 de novo PD patients of who 14 were evaluated again after 2–3 years of disease progression. Statistical analysis used random-effects models.
The only significant difference between PD patients and controls was a higher glutamine (Gln) concentration in the putamen ipsilateral to the hemibody with predominant motor signs (Visit 1: 6.0 ± 0.4 mM vs. 5.2 ± 0.2 mM, p < 0.05; Visit 2: 6.2 ± 0.3 mM vs. 5.2 ± 0.2 mM, p < 0.05). At Visit 1, PD patients had higher Glu and Gln levels in the putamen ipsilateral versus contralateral to dominant clinical signs (Glu: 12.2 ± 0.6 mM vs. 10.4 ± 0.6 mM, p < 0.05; Gln: 6.0 ± 0.4 mM vs. 4.8 ± 0.4 mM, p < 0.05; Glu and Gln pool (Glx): 17.9 ± 0.8 mM vs. 14.7 ± 1.1 mM, p < 0.05). At Visit 2, the sum of the two metabolites remained significantly higher in the ipsilateral versus contralateral putamen (Glx: 18.3 ± 0.6 mM vs. 16.1 ± 0.9 mM, p < 0.05).
In de novo PD patients, the putamen ipsilateral to the more affected hemibody showed elevated Gln versus controls and elevated Glu and Gln concentrations versus the contralateral side. Abnormalities in Glu metabolism therefore occur early in PD but unexpectedly in the putamen contralateral to the more damaged hemisphere, suggesting they are not dependent solely on dopamine loss.
•MRS assesses glutamate, glutamine levels from the putamen of de novo parkinsonian patients.•Glutamate, glutamine levels are higher in the putamen ipsilateral to clinical signs.•Abnormalities in Glutamate metabolism therefore occur early in Parkinson Disease.•However, changes occur unexpectedly in the putamen of the less damaged hemisphere.•Metabolic changes are not dependent solely on dopamine loss.]]></abstract><pub>Elsevier Ltd</pub><pmid>35613535</pmid><doi>10.1016/j.parkreldis.2022.05.007</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-3778-7161</orcidid><orcidid>https://orcid.org/0000-0002-9234-2344</orcidid><orcidid>https://orcid.org/0000-0002-3786-1053</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1353-8020 |
| ispartof | Parkinsonism & related disorders, 2022-06, Vol.99, p.65-72 |
| issn | 1353-8020 1873-5126 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03882060v1 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | 1H magnetic Resonance spectroscopy Glutamate Glutamine Life Sciences Neurons and Cognition Parkinson's disease Putamen |
| title | Glutamate cycle changes in the putamen of patients with de novo Parkinson's disease using 1H MRS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A53%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glutamate%20cycle%20changes%20in%20the%20putamen%20of%20patients%20with%20de%20novo%20Parkinson's%20disease%20using%201H%20MRS&rft.jtitle=Parkinsonism%20&%20related%20disorders&rft.au=Chassain,%20Carine&rft.date=2022-06&rft.volume=99&rft.spage=65&rft.epage=72&rft.pages=65-72&rft.issn=1353-8020&rft.eissn=1873-5126&rft_id=info:doi/10.1016/j.parkreldis.2022.05.007&rft_dat=%3Cproquest_hal_p%3E2670063366%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2670063366&rft_id=info:pmid/35613535&rft_els_id=S1353802022001341&rfr_iscdi=true |